Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
Condition(s) studied
Investigational drug(s) / intervention(s)
Test product RV3278BB-OS0386: Cosmetic product RV3278BB-OS0386 to be applied twice a day on the face during the whole study
Control product RV3278B-OS0548: Cosmetic product RV3278B-OS0548 to be applied twice a day on the face during the whole study
Study summary
The aim of this study is to evaluate the efficacy of the RV3278B-OS0386 cosmetic product, compared to the control product in managing acne relapse during the 12-month maintenance phase follow-up after oral isotretinoin treatment in adult subjects with facial acne.
Eligibility
Primary outcome measure(s)
- Acne relapse rate — From Visit 1 (Day 1) to Visit 6 (Month 12 or early termination )
The acne relapse rate is defined as percentage of subjects experiencing acne relapse on the face according to the investigator
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre de santé Sabouraud | Paris | France | |
| Humanitas Research Hospital - Unita dermatologica | Milan | Italy | |
| Istituto Dermopatico dell'Immacolata in Roma | Roma | Italy | |
| Dr. E.Karamon Private Practice | Malbork | Poland | |
| Dr. I.Karamon Private Practice | Gdansk | Poland |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07341659 on ClinicalTrials.gov ↗ ← All trials in Italy